Reversal of the antilipolytic effect of prostaglandin E 2  by an oxazepine derivative (SC-19220).
D000085:Acetates / Q000494:pharmacology; D000273:Adipose Tissue / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D003989:Dibenzoxazepines / Q000494:pharmacology*; D004357:Drug Synergism; D004837:Epinephrine / Q000494:pharmacology; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D005990:Glycerol / Q000378:metabolism; D006834:Hydrazines / Q000494:pharmacology; D066298:In Vitro Techniques; D050356:Lipid Metabolism; D008297:Male; D011448:Prostaglandin Antagonists; D011453:Prostaglandins / Q000494:pharmacology; D051381:Rats
D000085:Acetates; D003989:Dibenzoxazepines; D005230:Fatty Acids, Nonesterified; D006834:Hydrazines; D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D005990:Glycerol; D004837:Epinephrine